Ximbio is pleased to announce a new partnership with UbiQ Bio in the Netherlands. The agreement means Ximbio will now manage the sale and out-licence of a novel monoclonal against yeast ubiquitinylated histone H2B, with the aim of making it more widely available to the scientific community.
UbiQ Bio originally listed the antibody under Ximbio's free model. Following the deposit the company received a number of enquiries which motivated them to consider the Ximbio portfolio managed model.
UbiQ Bio develops and commercialises ubiquitinated peptides, ubiquitin-based reagents and high throughput assays, which enable and expedite drug discovery in the rapidly expanding ubiquitin field.
Ximbio is an online reagents portal for the life science community and has been developed to change the way that research reagents are searched, sourced and shared. It aims to broaden the range of tools available to scientists globally and support and advance life science research.
Join the ever-growing global Ximbio community. Register and receive updates about new reagents, institutes and new features being added to the website.